Search

Displaying results 3671 - 3680 of 10000 in total
  1. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy. … Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels

  2. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency. … [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in

  3. Drug

    Epirubicin

    go.drugbank.com/drugs/DB00445
    ApprovedInvestigational

    An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.

  4. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

  5. Drug

    Pyrazoloacridine

    go.drugbank.com/drugs/DB12549
    Investigational

    Pyrazoloacridine has been used in trials studying the treatment of Lung Cancer, Liver Cancer, Breast Cancer, Melanoma (Skin), and Metastatic Cancer, among others.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the … It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.

  7. Drug

    Doxorubicin

    go.drugbank.com/drugs/DB00997
    ApprovedInvestigational

    Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. … [A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin

  8. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737]. … or as an alternative to erythromycin treatment [A176170].

  9. Drug

    Methdilazine

    go.drugbank.com/drugs/DB00902
    Approved

    It is used in the treatment of various dermatoses to relieve pruritus.

  10. Drug

    GTI-2501

    go.drugbank.com/drugs/DB05406
    Experimental

    GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. … The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer.